製品の概要

  • 製品名Anti-Cyclin D1 antibody
    Cyclin D1 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to Cyclin D1
  • アプリケーション適用あり: ELISA, IHC-P, WBmore details
  • 種交差性
    交差種: Mouse, Human
  • 免疫原

    Synthetic non-phosphopeptide derived from human Cyclin D1 around the phosphorylation site of threonine 286.

  • ポジティブ・コントロール
    • Jurkat cell extract, treated with EGF (200ng/ml, 30mins), human brain tissue.

製品の特性

関連製品

アプリケーション

Our Abpromise guarantee covers the use of ab61758 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
ELISA
IHC-P
WB
  • 追加情報ELISA: 1/40,000.
    IHC-P: 1/50 - 1/100.
    WB: 1/500 - 1/1000. Detect bands of approximately 31 and 21 kDa (predicted molecular weight: 31 kDa).


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 機能Essential for the control of the cell cycle at the G1/S (start) transition.
    • 関連疾患Note=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
      Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
      Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
    • 配列類似性Belongs to the cyclin family. Cyclin D subfamily.
    • 翻訳後修飾Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
      Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
    • 細胞内局在Nucleus.
    • Information by UniProt
    • 参照データベース
    • 別名
      • AI327039 antibody
      • B cell CLL/lymphoma 1 antibody
      • B cell leukemia 1 antibody
      • B cell lymphoma 1 protein antibody
      • B-cell lymphoma 1 protein antibody
      • BCL 1 antibody
      • BCL-1 antibody
      • BCL-1 oncogene antibody
      • BCL1 antibody
      • BCL1 oncogene antibody
      • ccnd1 antibody
      • CCND1/FSTL3 fusion gene, included antibody
      • CCND1/IGHG1 fusion gene, included antibody
      • CCND1/IGLC1 fusion gene, included antibody
      • CCND1/PTH fusion gene, included antibody
      • CCND1_HUMAN antibody
      • cD1 antibody
      • Cyl 1 antibody
      • D11S287E antibody
      • G1/S specific cyclin D1 antibody
      • G1/S-specific cyclin-D1 antibody
      • Parathyroid adenomatosis 1 antibody
      • PRAD1 antibody
      • PRAD1 oncogene antibody
      • U21B31 antibody
      see all

    Anti-Cyclin D1 antibody 画像

    • Human brain tissue stained with ab61758 at 1/50 dilution, with and without the immunising peptide.
    • All lanes : Anti-Cyclin D1 antibody (ab61758) at 1/500 dilution

      Lane 1 : extract from Jurkat cells, treated with EGF (200ng/ml, 30mins).
      Lane 2 : extract from Jurkat cells, treated with EGF (200ng/ml, 30mins), and the immunising peptide.


      Predicted band size : 31 kDa
      Observed band size : 31 kDa
      Additional bands at : 21 kDa. We are unsure as to the identity of these extra bands.

    Anti-Cyclin D1 antibody (ab61758) 使用論文

    This product has been referenced in:

    See all 3 Publications for this product

    Product Wall

    Thank you for contacting us.
    If we list an antibody as tested, that means the product has been validated for that application and we will cover it under our Abpromise guarantee. If we don't list an application as tested, it generally means that we...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"